Dossier assessment
Lisocabtagene maraleucel (follicular lymphoma) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Lisocabtagene maraleucel (follicular lymphoma) – Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Lisocabtagene maraleucel (follicular lymphoma) – Benefit assessment according to §35a Social Code Book V
Dossier assessment
Adult patients with relapsed or refractory follicular lymphoma after 2 or more lines of systemic therapy
Added benefit not proven
Press releases
Lisocabtagene maraleucel in follicular lymphoma: mysterious study discontinuation
Project details
- Project no.
- A25-47
- Commission
- Commission awarded on 11.04.2025 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
- DOI
https://doi.org/10.60584/A25-47_en
Connected Projects
-
Dossier assessment
Lisocabtagene maraleucel (DLBCL, PMBCL and FL3B) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Lisocabtagene maraleucel (DLBCL, HGBCL, PMBCL and FL3B, each after one prior therapy) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Lisocabtagene maraleucel (mantle cell lymphoma) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed